Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 2/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.35 |
| ▸ | GLS2 | Q9UI32 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13174362 | 1.00 | STAT3 (0.47) | STAT3PTPN1ACHEBACE1ALOX5 | |
| SCHEMBL15214280 | 0.84 | PTPN1 (0.54) | STAT3PTPN1ACHEBACE1ALOX5 | |
| SCHEMBL7053777 | 0.84 | PTPN1 (0.54) | STAT3PTPN1ACHEBACE1ALOX5 | |
| SCHEMBL18104368 | 0.82 | STAT3 (0.47) | STAT3PTPN1ACHEBACE1ALOX5 | |
| SCHEMBL20754352 | 0.78 | STAT3 (0.41) | STAT3PTPN1ACHEBACE1ALOX5 | |
| SCHEMBL17817858 | 0.76 | STAT3 (0.81) | STAT3PTPN1ACHEBACE1 | |
| SCHEMBL18840113 | 0.76 | PTPN1 (0.43) | STAT3PTPN1ACHEBACE1ALOX5 | |
| SCHEMBL13174443 | 0.76 | PTPN1 (0.47) | STAT3PTPN1ACHEBACE1ALOX5 | |
| SCHEMBL17817848 | 0.75 | ALOX5 (0.45) | STAT3PTPN1ACHEBACE1ALOX5 | |
| Bromide SCHEMBL22265994 | 0.74 | PTPN1 (0.46) | STAT3PTPN1ACHEBACE1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160279154-A1 | MITOCONDRIALLY-TARGETED TIMOQUINONES AND TOLUQUINONES | MITOTECH SA (LU) | 2016-09-29 | — | — | US | disclosed |
| US-20160279154-A1 | MITOCONDRIALLY-TARGETED TIMOQUINONES AND TOLUQUINONES | MITOTECH SA (LU) | 2016-09-29 | — | — | US | disclosed |
| US-20160279154-A1 | MITOCONDRIALLY-TARGETED TIMOQUINONES AND TOLUQUINONES | MITOTECH SA (LU) | 2016-09-29 | — | — | US | disclosed |
| US-20160200749-A1 | BIOLOGICALLY ACTIVE COMPOUNDS SPECIFICALLY DELIVERED INTO MITOCHONDRIA | MITOTECH SA (LU) | 2016-07-14 | — | — | US | disclosed |
| US-20160200749-A1 | BIOLOGICALLY ACTIVE COMPOUNDS SPECIFICALLY DELIVERED INTO MITOCHONDRIA | MITOTECH SA (LU) | 2016-07-14 | — | — | US | disclosed |
| US-20160200749-A1 | BIOLOGICALLY ACTIVE COMPOUNDS SPECIFICALLY DELIVERED INTO MITOCHONDRIA | MITOTECH SA (LU) | 2016-07-14 | — | — | US | disclosed |
| EP-3030267-A2 | MITOCHONDRIALLY-TARGETED TIMOQUINONES AND TOLUQUINONES | Mitotech SA (LU) | 2016-06-15 | — | — | EP | disclosed |
| US-9328130-B2 | Method of treating organism by biologically active compounds specifically delivered into mitochondria, pharmaceutical composition required for the use of the method and a compound applicable for this purpose | MITOTECH S.A. (LU) | 2016-05-03 | — | — | US | disclosed |
| US-9328130-B2 | Method of treating organism by biologically active compounds specifically delivered into mitochondria, pharmaceutical composition required for the use of the method and a compound applicable for this purpose | MITOTECH S.A. (LU) | 2016-05-03 | — | — | US | disclosed |
| US-9328130-B2 | Method of treating organism by biologically active compounds specifically delivered into mitochondria, pharmaceutical composition required for the use of the method and a compound applicable for this purpose | MITOTECH S.A. (LU) | 2016-05-03 | — | — | US | disclosed |
| US-20080176929-A1 | driven by proton electro-chemical potential; reduction of concentration of free radicals and reactive oxygen species in living cell; antiproliferative, antiinflammatory agent, antioxidant, disinfectant; wound healing, grafting; composition of antioxidant, linker, and charged lipophilic compound/peptide | MITOTECHNOLOGY LLC. (RU) | 2008-07-24 | — | — | US | disclosed |
| US-20080176929-A1 | driven by proton electro-chemical potential; reduction of concentration of free radicals and reactive oxygen species in living cell; antiproliferative, antiinflammatory agent, antioxidant, disinfectant; wound healing, grafting; composition of antioxidant, linker, and charged lipophilic compound/peptide | MITOTECHNOLOGY LLC. (RU) | 2008-07-24 | — | — | US | disclosed |
| US-20080176929-A1 | driven by proton electro-chemical potential; reduction of concentration of free radicals and reactive oxygen species in living cell; antiproliferative, antiinflammatory agent, antioxidant, disinfectant; wound healing, grafting; composition of antioxidant, linker, and charged lipophilic compound/peptide | MITOTECHNOLOGY LLC. (RU) | 2008-07-24 | — | — | US | disclosed |
| EP-1937277-A1 | METHOD OF ACTING UPON ORGANISM BY TARGETED DELIVERY OF BIOLOGICALY ACTIVE SUBSTANCES INTO M ITOCHONDRIA, PHARMACEUTICAL COMPOSITION FOR CARRYING OUT SAID METHOD, AND COMPOUND USED FOR THE PURPOSE | Limited Liability Company "Mitotechnology" (RU) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007046729-A1 | METHOD OF ACTING UPON ORGANISM BY TARGETED DELIVERY OF BIOLOGICALY ACTIVE SUBSTANCES INTO M ITOCHONDRIA, PHARMACEUTICAL COMPOSITION FOR CARRYING OUT SAID METHOD, AND COMPOUND USED FOR THE PURPOSE | LIMITED LIABILITY COMPANY 'MITOTECHNOLOGY' (RU) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007046729-A1 | METHOD OF ACTING UPON ORGANISM BY TARGETED DELIVERY OF BIOLOGICALY ACTIVE SUBSTANCES INTO M ITOCHONDRIA, PHARMACEUTICAL COMPOSITION FOR CARRYING OUT SAID METHOD, AND COMPOUND USED FOR THE PURPOSE | LIMITED LIABILITY COMPANY 'MITOTECHNOLOGY' (RU) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200749-A1 | BIOLOGICALLY ACTIVE COMPOUNDS SPECIFICALLY DELIVERED INTO MITOCHONDRIA | TFAM, MT-ND2, NDUFAB1 | STAT3 579/4885PTPN1 4385/4885ACHE 3510/4885 |
| US-20080176929-A1 | driven by proton electro-chemical potential; reduction of concentration of free radicals and reactive oxygen species in living cell; antiproliferative, antiinflammatory agent, antioxidant, disinfectant; wound healing, grafting; composition of antioxidant, linker, and charged lipophilic compound/peptide | PRDX5, PDF, MCU | STAT3 178/4885PTPN1 4244/4885ACHE 3733/4885 |
| US-20160279154-A1 | MITOCONDRIALLY-TARGETED TIMOQUINONES AND TOLUQUINONES | MT-ND2, MT-ND5, MT-ND1 | STAT3 1757/4885PTPN1 3818/4885ACHE 1683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.